Oncology

Latest News

FDA Grants Full Approval to Rybrevant in Lung Cancer
FDA Grants Full Approval to Rybrevant in Lung Cancer

March 1st 2024

Rybrevant is indicated to be used in combination with chemotherapy as a first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

PIC4U-stock.adobe.com
FDA Sets Review Date for Tislelizumab in Stomach Cancer

February 28th 2024

FDA Grants Priority Review for Second Epkinly Indication
FDA Grants Priority Review for Second Epkinly Indication

February 27th 2024

FDA Withdraws Approval of Pepaxto in Multiple Myeloma
FDA Withdraws Approval of Pepaxto in Multiple Myeloma

February 23rd 2024

FDA Approves Biweekly Dosing of Tecvayli for Multiple Myeloma
FDA Approves Biweekly Dosing of Tecvayli for Multiple Myeloma

February 21st 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.